system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Aging, Animals, Animals, Newborn, Female, Fetus, Flow Cytometry, Gestational Age, Graft Survival, Hematopoietic Stem Cell Transplantation, Injections, Intraperitoneal, Leukocyte Common Antigens, Mice, Mice, Inbred C57BL, Pregnancy.
user
Do postnatal booster injections increase engraftment after in utero stem cell transplantation? Context: The primary barrier to clinical application of in utero hematopoietic stem cell (HSC) transplantation is limited donor cell engraftment. We hypothesized that limited engraftment was due to competition between host and donor cells for available niches. We reasoned that increased engraftment might be achieved by performing multiple transplants separated by brief intervals to allow time for formation of new niches. To test this we performed multiple transplants in a congenic combination to avoid confounding immunologic effects. C57Pep3B (H2Kb, CD45.1) mice were used as donors of adult bone marrow and C57Bl/6 (H2Kb, CD45.2) mice were used as 14-day-gestation fetal recipients. All fetuses were injected intraperitoneally with 1 x 10(6) mononuclear cells. Boosted neonates were injected at Days 2, 4, and 7 of life with 5 x 10(6) cells. All animals were analyzed for donor cell engraftment by dual-color flow cytometry using CD45 and CD45.1 antigens. Results are reported as the mean +/- SD. Statistical analysis was performed using the two-tailed Student t test with P < 0.05 considered significant. Postnatally boosted animals demonstrated significantly elevated levels of donor cell engraftment (3.30 +/- 0.8%; n = 8; P < 0.00001) when compared to the control animals (0.69 +/- 0.5%; n = 9) as determined by peripheral blood analysis at 6 weeks of age. This elevated level of engraftment was stable long term.
assistant
Our results demonstrate a significant increase in donor cell engraftment with postnatal booster injections after in utero transplantation. This supports the hypothesis that a limited number of niches may be a major component of the barrier to engraftment. It also suggests that postnatal booster injections may be a viable therapeutic strategy for improving donor cell engraftment after in utero HSC transplantation. Final Decision: yes